A Phase 1 Study to Observe Safety and Tolerability of Single and Multiple Doses of TRK-820 in Subjects on Hemodialysis and to Observe the Effect on Uremic Pruritus
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Nalfurafine (Primary)
- Indications Pruritus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Toray Industries
- 19 Jul 2017 Status changed from active, no longer recruiting to completed.
- 06 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Jul 2017.
- 06 Jun 2017 Status changed from recruiting to active, no longer recruiting.